Esophageal Dysphagia Global Market Report 2024

The global esophageal dysphagia market has grown strongly in recent years. It will grow from $1.96 billion in 2023 to $2.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to aging population, gastroesophageal reflux disease (gerd), advances in endoscopy, esophageal motility testing.

The global esophageal dysphagia market is expected to see strong growth in the next few years. It will grow to $2.67 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to obesity epidemic, minimally invasive procedures, personalized medicine, global expansion of esophageal dysphagia care. Major trends in the forecast period include patient-centered care, telehealth and remote monitoring, nutritional support, research collaboration.

The upward trend in smoking rates is anticipated to fuel the expansion of the esophageal dysphagia market in the foreseeable future. Smoking, in this context, pertains to the consumption of tobacco products, including cigarettes, cigars, or pipes. It's noteworthy that smoking can exacerbate esophageal dysphagia, potentially leading to various health complications, such as irritation and damage to the esophagus. The treatment for esophageal dysphagia plays a crucial role in aiding individuals afflicted by the condition, offering improved nutrition and hydration, reduced aspiration risk, and an enhanced quality of life. For example, data from Statistics Canada in July 2022 revealed a 5.8% increase in cigarette production compared to June 2021. Furthermore, the total number of cigarettes sold saw a 1.3% rise from May 2022, reaching 1.4 billion in June 2022. Consequently, the increasing number of smokers is a driving force behind the esophageal dysphagia market.

The growing incidence of strokes is projected to be a significant driver of the esophageal dysphagia market's growth in the coming years. Stroke, a condition resulting from a ruptured blood vessel in the brain or an obstruction in blood flow to specific brain regions, affects the areas of the brain responsible for swallowing and can consequently lead to esophageal dysphagia. As an illustration, data from the Centers for Disease Control and Prevention in May 2023 indicated that in 2021, 1 in 6 cardiovascular disease-related deaths were attributed to strokes, with an annual occurrence of 795,000 stroke cases. Hence, the increasing prevalence of strokes is contributing to the growth of the esophageal dysphagia market.

The esophageal dysphagia market faces potential hindrances due to the side effects associated with medications prescribed for the condition. These side effects encompass dry mouth, constipation, nausea, and, in some instances, dizziness or drowsiness. Such adverse effects can significantly impact a patient's quality of life and their willingness to adhere to the prescribed treatment, ultimately affecting market growth. For example, a study conducted by the American Gastroenterological Association in May 2022 revealed that patients grappling with esophageal dysphagia express substantial concerns about the side effects of dysphagia medications and tubes. Prolonged usage of dysphagia medications, including substances like botulinum toxin and opioids, may lead to undesirable outcomes like dry mouth, constipation, and nausea. Hence, the presence of medication-related side effects poses a barrier to the growth of the esophageal dysphagia market.

Leading companies within the esophageal dysphagia market are actively engaged in the development of cutting-edge products that incorporate advanced technologies, such as pharyngeal electrical stimulation (PES) technology. These innovations are aimed at strengthening their relationships with existing customers. Pharyngeal electrical stimulation (PES) technology represents a therapeutic approach specifically designed to address certain swallowing disorders, notably dysphagia resulting from neurological conditions or related factors. As an illustration, in October 2022, Phagenesis Ltd., a UK-based company specializing in dysphagia care, introduced the Phagenyx neurostimulation system, built upon pharyngeal electrical stimulation technology. This system offers a novel rehabilitation treatment for post-stroke dysphagia by enhancing swallowing performance in individuals with neurogenic dysphagia associated with stroke. The method involves direct pharyngeal stimulation using location-specific intraluminal catheters introduced trans nasally. Furthermore, PES technology holds promise in enhancing the quality of life for dysphagia patients, reducing healthcare costs, and broadening its applicability to a wider spectrum of individuals with dysphagia.

In May 2023, Patheous Health Inc., a U.S.-based company specializing in dysphagia care, completed the acquisition of Carolina Speech Pathology LLC for an undisclosed sum. Through this strategic move, Patheous Health Inc. aims to broaden its reach, expand its array of services, and tap into additional talent, thereby gaining a competitive edge in the dysphagia healthcare market. Carolina Speech Pathology LLC is a U.S.-based developer of mobile dysphagia swallow imaging devices, designed to enhance esophageal dysphagia treatment.

Major players in the esophageal dysphagia market are Nestle Health Science S.A., Novartis AG, Fresenius Kabi AG, Abbott Laboratories, Danone S.A., F. Hoffmann-La Roche Ltd., Merck Sharp and Dohme Corp., Pfizer Inc., Ingredion Incorporated, Eikonix Ltd., Olympus Corporation, Eisai Co. Ltd., Aurobindo Pharma Ltd., Dr. Reddys Laboratories, Cook Medical Incorporated, Elekta AB, Johnson and Johnson Ltd., C.R. Bard Inc., Avanos Medical Inc., Cipla Ltd., Kent Precision Foods Group Inc., Nutricia Ltd., CP Kelco Inc., Atos Medical AB, AstraZeneca PLC, NinePoint Medical Inc., Torax Medical Inc., Hormel Health Labs Inc., Dysphagia Management Systems LLC, Biostage Inc.

North America was the largest region in the esophageal dysphagia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in esophageal dysphagia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the esophageal dysphagia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary treatments for esophageal dysphagia encompass esophageal dilation, surgical intervention, stent placement, laparoscopic Heller myotomy, medications, and lifestyle adjustments. Esophageal dilation is a medical procedure employed to widen a narrowed or constricted segment of the esophagus, commonly used to address esophageal dysphagia stemming from esophageal strictures. Diagnosis of esophageal dysphagia can be achieved through dynamic swallowing studies, X-rays, endoscopy, manometry, imaging scans, including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Various healthcare facilities, such as hospitals, clinics, ambulatory surgical centers, diagnostic centers, and research centers, serve as end-users for managing this condition.

This report provides esophageal dysphagia market statistics, including esophageal dysphagia industry global market size, regional shares, competitors with an esophageal dysphagia market share, detailed esophageal dysphagia market segments, market trends and opportunities and any further data you may need to thrive in the esophageal dysphagia industry. This esophageal dysphagia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esophageal dysphagia market consists of revenues earned by entities by providing services such as surgical assistance and physical therapy, clinical evaluation, impedance testing, dietary counseling and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The esophageal dysphagia market also includes the sales of feeding tubes, nasogastric tubes, nutritional solutions, thickeners, beverages, purees, dysphagia diets, esophageal dilation devices, surgical instruments, esophageal pH monitors, corticosteroids, antacids, proton-pump inhibitors (PPIs) and muscle relaxants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.